244 related articles for article (PubMed ID: 35052414)
41. Investigating sodium valproate as a treatment for McArdle disease in sheep.
Howell JM; Dunton E; Creed KE; Quinlivan R; Sewry C
Neuromuscul Disord; 2015 Feb; 25(2):111-9. PubMed ID: 25455802
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R; Martinuzzi A; Schoser B
Cochrane Database Syst Rev; 2010 Dec; (12):CD003458. PubMed ID: 21154353
[TBL] [Abstract][Full Text] [Related]
43. Clinical Presentation and Management of Severe Acute Renal Failure in McArdle Disease.
Hamadeh M; Nasrallah K; Ajami Z; Zeaiter R; Abbas L; Hamadeh S; Fares J
Clin Med Res; 2021 Jun; 19(2):90-93. PubMed ID: 33985978
[TBL] [Abstract][Full Text] [Related]
44. Pre- and peripartal management of a woman with McArdle disease: a case report.
Stopp T; Feichtinger M; Eppel W; Stulnig TM; Husslein P; Göbl C
Gynecol Endocrinol; 2018 Sep; 34(9):736-739. PubMed ID: 29560763
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R; Martinuzzi A; Schoser B
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD003458. PubMed ID: 25391139
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic options in other metabolic myopathies.
Vorgerd M
Neurotherapeutics; 2008 Oct; 5(4):579-82. PubMed ID: 19019309
[TBL] [Abstract][Full Text] [Related]
47. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry.
Lucia A; Ruiz JR; Santalla A; Nogales-Gadea G; Rubio JC; García-Consuegra I; Cabello A; Pérez M; Teijeira S; Vieitez I; Navarro C; Arenas J; Martin MA; Andreu AL
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):322-8. PubMed ID: 22250184
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal case study and phenotypic multimodal characterization of McArdle disease-linked retinopathy: insight into pathomechanisms.
Vaclavik V; Naderi F; Schaller A; Escher P
Ophthalmic Genet; 2020 Feb; 41(1):73-78. PubMed ID: 32124677
[No Abstract] [Full Text] [Related]
49. [MCARDLE'S DISEASE AND PHYSICAL ACTIVITY - A MIXED BLESSING].
Nemet D; Eliakim A
Harefuah; 2021 Jun; 160(6):377-381. PubMed ID: 34160155
[TBL] [Abstract][Full Text] [Related]
50. Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease.
Pareja-Galeano H; Santos-Lozano A; Morán M; Sanchis-Gomar F; Alis R; Santalla A; San Juan AF; Díez-Bermejo J; Martín MA; Arenas J; Lucia A
Curr Pharm Des; 2016; 22(18):2657-63. PubMed ID: 26861723
[TBL] [Abstract][Full Text] [Related]
51. [Morphological and biochemical studies on glycogenosis type V (McArdle) (author's transl)].
Pongratz D; Schaub J; Koppenwallner C; Hübner G
Klin Wochenschr; 1981 Sep; 59(18):1053-9. PubMed ID: 6795385
[TBL] [Abstract][Full Text] [Related]
52. Novel mutation in the PYGM gene resulting in McArdle disease.
Rubio JC; Lucia A; Fernández-Cadenas I; Cabello A; Blázquez A; Gámez J; Andreu AL; Martín MA; Arenas J
Arch Neurol; 2006 Dec; 63(12):1782-4. PubMed ID: 17172620
[TBL] [Abstract][Full Text] [Related]
53. Differential glucose metabolism in mice and humans affected by McArdle disease.
Krag TO; Pinós T; Nielsen TL; Duran J; García-Rocha M; Andreu AL; Vissing J
Am J Physiol Regul Integr Comp Physiol; 2016 Aug; 311(2):R307-14. PubMed ID: 27280431
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: expression and re-expression of glycogen phosphorylase.
Howell JM; Walker KR; Davies L; Dunton E; Everaardt A; Laing N; Karpati G
Neuromuscul Disord; 2008 Mar; 18(3):248-58. PubMed ID: 18343113
[TBL] [Abstract][Full Text] [Related]
55. Clinical and laboratory features of patients with myophosphorylase deficiency (McArdle disease).
Miteff F; Potter HC; Allen J; Teoh H; Roxburgh R; Hutchinson DO
J Clin Neurosci; 2011 Aug; 18(8):1055-8. PubMed ID: 21658951
[TBL] [Abstract][Full Text] [Related]
56. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease.
Vissing J; Duno M; Schwartz M; Haller RG
Brain; 2009 Jun; 132(Pt 6):1545-52. PubMed ID: 19433441
[TBL] [Abstract][Full Text] [Related]
57. [Massive rhabdomyolysis revealing a McArdle disease].
Loupy A; Pouchot J; Hertig A; Bonnard G; Bouvard E; Rondeau E
Rev Med Interne; 2007 Jul; 28(7):501-3. PubMed ID: 17383055
[TBL] [Abstract][Full Text] [Related]
58. Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency.
Preisler N; Cohen J; Vissing CR; Madsen KL; Heinicke K; Sharp LJ; Phillips L; Romain N; Park SY; Newby M; Wyrick P; Mancias P; Galbo H; Vissing J; Haller RG
Mol Genet Metab; 2017 Nov; 122(3):117-121. PubMed ID: 28882528
[TBL] [Abstract][Full Text] [Related]
59. Muscle fiber type proportion and size is not altered in mcardle disease.
Henning F; Cunninghame CA; Martín MA; Rubio JC; Arenas J; Lucia A; HernáNdez-Laín A; Kohn TA
Muscle Nerve; 2017 Jun; 55(6):916-918. PubMed ID: 27859426
[TBL] [Abstract][Full Text] [Related]
60. A 1-year-old infant with McArdle disease associated with hyper-creatine kinase-emia during febrile episodes.
Ito Y; Saito K; Shishikura K; Suzuki H; Yazaki E; Hayashi K; Fukuda T; Ito M; Sugie H; Osawa M
Brain Dev; 2003 Sep; 25(6):438-41. PubMed ID: 12907279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
